Monte Rosa Therapeutics (GLUE) Operating Leases (2023 - 2025)
Historic Operating Leases for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $35.9 million.
- Monte Rosa Therapeutics' Operating Leases fell 1029.91% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 1029.91%. This contributed to the annual value of $39.0 million for FY2024, which is 903.98% down from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Operating Leases is $35.9 million, which was down 1029.91% from $37.0 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Operating Leases peaked at $44.4 million during Q2 2023, and registered a low of $35.9 million during Q3 2025.
- Over the past 3 years, Monte Rosa Therapeutics' median Operating Leases value was $40.9 million (recorded in 2024), while the average stood at $40.6 million.
- Its Operating Leases has fluctuated over the past 5 years, first crashed by 332.29% in 2024, then plummeted by 1029.91% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Operating Leases (Quarter) stood at $42.9 million in 2023, then decreased by 9.04% to $39.0 million in 2024, then decreased by 7.88% to $35.9 million in 2025.
- Its Operating Leases stands at $35.9 million for Q3 2025, versus $37.0 million for Q2 2025 and $38.0 million for Q1 2025.